News
-
-
PRESS RELEASE
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
Spexis receives second extension from SIX Exchange Regulation AG to publish its 2023 annual report by July 31, 2024, providing unaudited financial statements and an update on the dispute with SPRIM -
-
PRESS RELEASE
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Spexis AG receives approval to extend deadline for publishing 2023 annual report and audited financials until May 31, 2024, due to ongoing legal discussions and negotiations with creditors -
-
PRESS RELEASE
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis AG extends moratorium and receives payment for antibiotics program sale while reverting lonodelestat license from Santhera -
PRESS RELEASE
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Spexis AG announces the closing of the sale of a preclinical antibiotics program to Basilea, which will pay up to CHF 2 million for the program. The program targets Gram-negative bacteria, including multidrug-resistant strains. The sale is part of Spexis' strategy to divest non-core programs and assets to focus on rare diseases and oncology -
-
PRESS RELEASE
Spexis Announces Changes to the Executive Committee
-
